RVD O
induction O
and O
autologous O
stem O
cell O
transplantation O
followed O
by O
lenalidomide B-DESC
maintenance I-DESC
in O
newly O
diagnosed O
multiple O
myeloma O
: O
a O
phase B-STYPE
2 I-STYPE
study I-STYPE
of O
the O
Finnish O
Myeloma O
Group O
RVD O
induction O
and O
autologous O
stem O
cell O
transplantation O
followed O
by O
lenalidomide B-DESC
maintenance I-DESC
in O
newly O
diagnosed O
multiple O
myeloma O
: O
a O
phase B-STYPE
2 I-STYPE
study I-STYPE
of O
the O
Finnish O
Myeloma O
Group O
31 O
October O
2019 O
31 O
October O
2019 O
SiniLuoma B-AUTH

Hematology O
- O
Oncology O
Unit O
Oulu O
University O
Hospital O
Oulu O
Finland O
MerviPutkonen B-AUTH
Hematology O
Unit O
Turku O
University O
Hospital O
Turku O
Finland O
Hematology O
Unit O
Turku O
University O
Hospital O
Turku O
Finland O
HannaOllikainen B-AUTH
Department O
of O
Medicine O
Satakunta O
Central O
Hospital O
Pori O
Finland O
Department O
of O
Medicine O
Satakunta O
Central O
Hospital O
Pori O
Finland O
VenlaTerävä B-AUTH
Hematology O
Unit O
Tampere O
University O
Hospital O
Tampere O
Finland O
Hematology O
Unit O
Tampere O
University O
Hospital O
Tampere O
Finland O
MarjaSankelo B-AUTH
Hematology O
Unit O
Tampere O
University O
Hospital O
Tampere O
Finland O
Hematology O
Unit O
Tampere O
University O
Hospital O
Tampere O
Finland O
AnuPartanen B-AUTH
Department O
of O
Medicine O
Kuopio O
University O
Hospital O
Kuopio O
Finland O
Department O
of O
Medicine O
Mikkeli O
Central O
Hospital O
Mikkeli O
Finland O
Department O
of O
Medicine O
Kuopio O
University O
Hospital O
Kuopio O
Finland O
Department O
of O
Medicine O
Mikkeli O
Central O
Hospital O
Mikkeli O
Finland O
& O
Kirsi B-AUTH
Launonen I-AUTH

Länsi O
- O
Pohja O
Central O
Hospital O
Kemi O
Finland O
AnuRäsänen B-AUTH
Department O
of O
Medicine O
Kymenlaakso O
Central O
Hospital O
Kotka O
Finland O
Department O
of O
Medicine O
Kymenlaakso O
Central O
Hospital O
Kotka O
Finland O
AnuSikiö B-AUTH
Department O
of O
Medicine O

Kanta O
- O
Häme O
Central O
Hospital O
Hämeenlinna O
Finland O
PiotrBazia B-AUTH
Department O
of O
Medicine O
Kainuu O
Central O
Hospital O
Kajaani O
Finland O
Department O
of O
Medicine O
Kainuu O
Central O
Hospital O
Kajaani O
Finland O
KristiinaKananen B-AUTH
Department O
of O
Medicine O
Kainuu O
Central O
Hospital O
Kajaani O
Finland O
Department O
of O
Medicine O
Kainuu O
Central O
Hospital O
Kajaani O
Finland O
JuhaLievonen B-AUTH
Comprehensive O
Cancer O
Center O
Department O
of O
Hematology O

Helsinki O
University O
Hospital O
and O
University O
of O
Helsinki O
Helsinki O
Finland O
TuomasSelander B-AUTH
Science O
Service O
Center O
Kuopio O
University O
Hospital O
Kuopio O
Finland O
Science O
Service O
Center O
Kuopio O
University O
Hospital O
Kuopio O
Finland O
Tarja B-AUTH
- I-AUTH
TerttuPelliniemi I-AUTH
Fimlab O
Laboratories O
Ltd O
Tampere O
Finland O
Fimlab O
Laboratories O
Ltd O
Tampere O
Finland O
SorellaIlveskero B-AUTH

HUSLAB O
Helsinki O
University O
Hospital O
Helsinki O
Finland O
VirvaHuotari B-AUTH
Fimlab O
Laboratories O
Ltd O
Tampere O
Finland O
NordLab O
Oulu O
Oulu O
University O
Hospital O
Oulu O
Finland O
Fimlab O
Laboratories O
Ltd O
Tampere O
Finland O
NordLab O
Oulu O
Oulu O
University O
Hospital O
Oulu O
Finland O
PenttiMäntymaa B-AUTH

RVD O
induction O
and O
autologous O
stem O
cell O
transplantation O
followed O
by O
lenalidomide B-DESC
maintenance I-DESC
in O
newly O
diagnosed O
multiple O
myeloma O
: O
a O
phase B-STYPE
2 I-STYPE
study I-STYPE
of O
the O
Finnish O
Myeloma O
Group O
31 O
October O
2019 O

RVD O
induction O
and O
autologous O
stem O
cell O
transplantation O
followed O
by O
lenalidomide B-DESC
maintenance I-DESC
in O
newly O
diagnosed O
multiple O
myeloma O
: O
a O
phase B-STYPE
2 I-STYPE
study I-STYPE
of O
the O
Finnish O
Myeloma O
Group O
SiniLuoma B-AUTH
Comprehensive O
Cancer O
Center O
Department O
of O
Hematology O

Finland O
Tampere O
Finland O
AnuPartanen B-AUTH
Department O
of O
Medicine O
Kuopio O
University O
Hospital O
Kuopio O
Finland O
Department O
of O
Medicine O
Mikkeli O
Central O
Hospital O
Mikkeli O
Finland O
Department O
of O
Medicine O
Kuopio O
University O
Hospital O
Kuopio O
Finland O
Department O
of O
Medicine O
Mikkeli O
Central O
Hospital O
Mikkeli O

Finland O
Helsinki O
Finland O
VirvaHuotari B-AUTH
Fimlab O
Laboratories O
Ltd O
Tampere O
Finland O
NordLab O
Oulu O
Oulu O
University O
Hospital O
Oulu O
Finland O
Fimlab O
Laboratories O
Ltd O
Tampere O
Finland O
NordLab O
Oulu O
Oulu O
University O
Hospital O
Oulu O

Finland O
Kuopio O
Finland O
RVD O
induction O
and O
autologous O
stem O
cell O
transplantation O
followed O
by O
lenalidomide B-DESC
maintenance I-DESC
in O
newly O
diagnosed O
multiple O
myeloma O
: O
a O
phase B-STYPE
2 I-STYPE
study I-STYPE
of O
the O
Finnish O
Myeloma O
Group O
31 O
October O
2019 O
31 O
October O
2019 O
31 O
October O
2019 O
10.1007 O
/ O
s00277 O
- O
019 O
- O
03815 O
- O
7 O
Received O
: O
17 O
December O
2018 O
/ O
Accepted O
: O
8 O
October O
2019 O
# O
The O
Author(s O
) O
2019 O

Autologous O
stem O
cell O
transplantation O
( O
ASCT O
) O
combined O
with O
novel O
agents O
is O
the O
standard O
treatment O
for O
transplant O
- O
eligible O
, O
newly O
diagnosed O
multiple O
myeloma O
( O
NDMM O
) O
patients O
. O
Bortezomib O
( O
V O
) O
plus O
dexamethasone O
( O
D O
) O
combined O
either O
with O
cyclophosphamide O
( O
CY O
) O
, O
thalidomide O
, O
liposomal O
doxorubicin O
, O
or O
lenalidomide O
( O
R O
) O
are O
recommended O
for O
induction O
treatment O
[ O
1 O
] O
. O
RVD O
is O
not O
yet O
approved O
by O
the O
European O
Medicines O
Agency O
( O
EMA O
) O
for O
first O
- O
line O
treatment O
in O
transplant O
- O
eligible O
NDMM O
patients O
. O

Lenalidomide O
maintenance O
after O
ASCT O
prolongs O
progression O
- O
free O
survival O
( O
PFS O
) O
[ O
2][3][4 O
] O
and O
overall O
survival O
( O
OS O
) O
[ O
3 O
] O
and O
is O
approved O
by O
EMA O
and O
Food O
and O
Drug O
Administration O
( O
FDA O
) O
for O
NDMM O
patients O
after O
ASCT O
until O
progression O
. O
The O
three O
randomized O
controlled O
trials O
( O
RCTs O
) O
evaluating O
lenalidomide O
maintenance O
were O
included O
in O
a O
meta O
- O
analysis O
[ O
5 O
] O
which O
demonstrated O
a O
significant O
PFS O
and O
OS O
benefit O
with O
lenalidomide O
maintenance O
after O
ASCT O
when O
compared O
with O
placebo O
or O
observation O
. O
The O
optimal O
duration O
of O
lenalidomide O
maintenance O
is O
a O
matter O
of O
debate O
. O
In O
Cancer O
and O
Leukemia O
Group O
B O
( O
CALGB O
) O
[ O
3 O
] O
and O
Intergroupe O
Francophone O
du O
Myelome O
( O
IFM O
) O
[ O
2 O
] O
trials O
, O
patients O
received O
post O
- O
ASCT O
placebo O
or O
continuous O
lenalidomide O
10 O
mg O
for O
3 O
months O
escalated O
then O
to O
15 O
mg O
, O
until O
disease O
progression O
, O
intolerable O
side O
effects O
, O
or O
death O
. O
The O
IFM O
group O
decided O
to O
stop O
the O
treatment O
in O
the O
lenalidomide O
arm O
due O
to O
the O
noticed O
risk O
of O
secondary O
primary O
malignancies O
( O
SPMs O
) O
in O
opposite O
to O
the O
CALGB O
trial O
where O
patients O
continued O
maintenance O
until O
progression O
. O
Based O
on O
the O
meta O
- O
analysis O
, O
the O
risk O
of O
death O
due O
to O
SPM O
was O
similar O
between O
lenalidomide O
and O
placebo O
or O
observation O
groups O
but O
there O
was O
a O
34 O
% O
reduction O
in O
risk O
to O
die O
of O
multiple O
myeloma O
( O
MM O
) O
in O
lenalidomide O
maintenance O
arm O
[ O
5 O
] O
. O

Mian O
et O
al O
. O
showed O
in O
their O
retrospective O
analysis O
a O
positive O
correlation O
between O
the O
duration O
of O
lenalidomide O
maintenance O
and O
OS O
[ O
6 O
] O
. O
In O
the O
study O
by O
Goldschmidt O
et O
al O
. O
, O
the O
patients O
were O
randomized O
to O
receive O
lenalidomide O
maintenance O
for O
2 O
years O
or O
until O
CR O
. O
In O
patients O
receiving O
lenalidomide O
for O
2 O
years O
, O
OS O
was O
higher O
[ O
7 O
] O
. O

The O
benefit O
of O
lenalidomide O
maintenance O
among O
high O
- O
risk O
( O
HR O
) O
patients O
has O
been O
demonstrated O
in O
Myeloma O
XI O
trial O
where O
the O
induction O
therapy O
was O
response O
- O
adjusted O
[ O
8 O
] O
. O
In O
Myeloma O
XI O
trial O
, O
1q O
gain O
was O
also O
included O
in O
HR O
aberrations O
in O
addition O
to O
t O
( O
4;14 O
) O
, O
t O
( O
14;16 O
) O
, O
and O
del17p O
. O
Patients O
receiving O
lenalidomide O
during O
both O
induction O
and O
maintenance O
had O
the O
best O
outcome O
, O
and O
also O
, O
the O
HR O
patients O
gained O
benefit O
of O
lenalidomide O
maintenance O
. O
However O
, O
this O
was O
not O
as O
clear O
as O
in O
standard O
- O
risk O
( O
SR O
) O
patients O
and O
patients O
with O
1q O
gain O
seemed O
to O
benefit O
more O
than O
the O
other O
HR O
patients O
. O

The O
impact O
of O
minimal O
residual O
disease O
( O
MRD O
) O
negativity O
for O
PFS O
and O
OS O
has O
been O
demonstrated O
in O
several O
trials O
[ O
9][10][11][12][13][14 O
] O
and O
it O
is O
also O
recommended O
for O
one O
of O
the O
primary O
endpoints O
for O
evaluating O
the O
approval O
of O
new O
drugs O
for O
MM O
[ O
9,15 O
] O
. O

This O
phase B-STYPE
2 I-STYPE
trial I-STYPE
of O
the O
Finnish O
Myeloma O
Group O
( O
FMG O
- O
MM02 O
) O
was O
designed O
to O
investigate O
the O
rate O
of O
serological O
responses O
, O
proportion O
of O
flow O
- O
MRD O
- O
negative O
( O
10 O
-4 O
) O
patients O
and O
patients O
in O
molecular O
remission O
( O
10 O
-5 O
) O
after O
RVD O
induction O
followed O
by O
ASCT B-DESC
, O
and O
lenalidomide B-DESC
maintenance I-DESC
in O
NDMM O
patients O
. O
We O
also O
focused O
on O
the O
safety O
of O
RVD O
induction O
and O
lenalidomide B-DESC
maintenance I-DESC
and O
improvement O
of O
responses O
during O
the O
maintenance O
. O
The O
study O
included O
also O
a O
randomized O
stem O
cell O
mobilization B-DESC
with I-DESC
CY I-DESC
plus I-DESC
filgrastim I-DESC
or O
filgrastim B-DESC
alone I-DESC
in O
order O
to O
examine O
the O
success O
of O
stem O
cell O
mobilization O
after O
lenalidomide O
- O
based O
induction O
. O

This O
study O
was O
nationally O
approved O
by O
the O
Research O
Ethics O
Committee O
of O
the O
Northern O
Savo O
Hospital O
District O
, O
and O
it O
was O
conducted O
according O
to O
the O
Declaration O
of O
Helsinki O
, O
International O
Conference O
of O
Harmonization O
and O
Guidelines O
for O
Good O
Clinical O
Practice O
. O
Written O
informed O
consent O
was O
obtained O
from O
all O
patients O
before O
inclusion O
. O
Key O
inclusion O
criteria O
were O
measurable O
, O
symptomatic O
, O
NDMM O
according O
to O
International O
Myeloma O
Working O
Group O
( O
IMWG O
) O
criteria O
[ O
16,17 O
] O
, O
age O
≤ O
70 O
years O
, O
and O
transplant O
- O
eligibility O
. O
Key O
exclusion O
criteria O
were O
peripheral O
neuropathy O
grade O
≥ O
2 O
, O
significant O
liver O
dysfunction O
, O
severe O
cardiac O
dysfunction O
, O
severe O
renal O
failure O
( O
glomerular O
filtration O
rate O
< O
15 O
ml O
/ O
min O
, O
unless O
in O
hemodialysis O
) O
, O
contraindication O
for O
the O
use O
of O
thromboprophylaxis O
or O
history O
of O
active O
malignancy O
during O
the O
past O
5 O
years O
with O
the O
exception O
of O
basal O
cell O
carcinoma O
of O
the O
skin O
or O
stage O
0 O
cervical O
carcinoma O
. O

This O
study O
was O
conducted O
at O
12 O
centers O
in O
Finland O
. O
The O
study O
design O
( O
Online O
Resource O
3 O
) O
and O
protocol O
( O
Online O
Resources O
4 O
- O
5 O
) O
are O
included O
in O
the O
supplementary O
material O
. O
The O
study O
is O
registered O
with O
number O
( O
NCT01790737 O
) O
on O
clinicaltrials.gov O
and O
was O
monitored O
with O
level O
two O
by O
independent O
Clinical O
Research O
Units O
of O
University O
Hospitals O
of O
Finland O
. O

Patients O
were O
initially O
treated O
with O
RVD B-DESC
induction O
comprising O
v - v - v - v - v - v - v - v - v - v - v - v - v - v - v - v - v - v - v - v - S T A R T - v - v - v - v - v - v - v - v - v - v - v - v - v - v - v - v - v - v - v - v
three B-DOSAGE
21-day I-DOSAGE
cycles I-DOSAGE
of I-DOSAGE
lenalidomide  B-DESC | I-DOSAGE
25 I-DOSAGE
mg I-DOSAGE
on I-DOSAGE
days I-DOSAGE
1 I-DOSAGE
- I-DOSAGE
14 I-DOSAGE
; I-DOSAGE
bortezomib  B-DESC | I-DOSAGE
1.3 I-DOSAGE
mg I-DOSAGE
/ I-DOSAGE
m I-DOSAGE
2 I-DOSAGE
on I-DOSAGE
days I-DOSAGE
1 I-DOSAGE
, I-DOSAGE
4 I-DOSAGE
, I-DOSAGE
8 I-DOSAGE
, I-DOSAGE
and I-DOSAGE
11 I-DOSAGE
subcutaneously I-DOSAGE
; I-DOSAGE
and I-DOSAGE
dexamethasone  B-DESC | I-DOSAGE
20 I-DOSAGE
mg I-DOSAGE
/ I-DOSAGE
day I-DOSAGE
on I-DOSAGE
days I-DOSAGE
1 I-DOSAGE
- I-DOSAGE
2 I-DOSAGE
, I-DOSAGE
4 I-DOSAGE
- I-DOSAGE
5 I-DOSAGE
, I-DOSAGE
8 I-DOSAGE
- I-DOSAGE
9 I-DOSAGE
, I-DOSAGE
and I-DOSAGE
11 I-DOSAGE
- I-DOSAGE
12 I-DOSAGE
^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - S T O P - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^
. O
Acyclovir O
and O
enoxaparin O
prophylaxis O
were O
given O
during O
induction O
( O
Online O
Resources O
4 O
- O
5 O
) O
. O
The O
mobilization B-DESC
in O
arm B-DESC
A I-DESC
was O
CY B-DOSAGE
2 I-DOSAGE
g I-DOSAGE
/ I-DOSAGE
m I-DOSAGE
2 I-DOSAGE
on I-DOSAGE
day I-DOSAGE
+ I-DOSAGE
1 I-DOSAGE
plus I-DOSAGE
filgrastim I-DOSAGE
5 I-DOSAGE
μg I-DOSAGE
/ I-DOSAGE
kg I-DOSAGE
starting I-DOSAGE
on I-DOSAGE
day I-DOSAGE
+ I-DOSAGE
4 I-DOSAGE
, O
and O
in O
arm B-DESC
B I-DESC
, O
filgrastim B-DOSAGE
10 I-DOSAGE
μg I-DOSAGE
/ I-DOSAGE
kg I-DOSAGE
alone I-DOSAGE
starting I-DOSAGE
on I-DOSAGE
day I-DOSAGE
+ I-DOSAGE
1 I-DOSAGE
. O
The O
goal O
was O
to O
collect O
at O
least O
3 O
× O
10 O
6 O
/kg O
CD34 O
+ O
cells O
for O
one O
transplant O
and O
6 O
× O
10 O
6 O
/kg O
if O
the O
second O
transplant O
was O
an O
option O
. O
The O
details O
of O
the O
apheresis O
procedure O
and O
guidelines O
for O
use O
of O
plerixafor O
as O
well O
as O
the O
results O
of O
the O
randomized O
mobilization O
study O
have O
been O
published O
previously O
[ O
18 O
] O
. O
Patients O
received O
a O
single O
ASCT B-DESC
after I-DESC
melphalan I-DESC
200 B-DOSAGE
mg I-DOSAGE
/ I-DOSAGE
m I-DOSAGE
2 I-DOSAGE
. O

Lenalidomide B-DESC
maintenance O
was O
started O
3 O
months O
after O
ASCT B-DESC
with O
a O
dose O
of O
10 B-DOSAGE
mg I-DOSAGE
/ I-DOSAGE
day I-DOSAGE
on I-DOSAGE
days I-DOSAGE
1 I-DOSAGE
- I-DOSAGE
21 I-DOSAGE
in I-DOSAGE
28-day I-DOSAGE
cycles I-DOSAGE
and O
was O
continued O
until O
progression O
or O
toxicity O
. O
The O
threshold O
for O
start O
of O
lenalidomide O
and O
each O
cycle O
was O
neutrophil O
count O
≥ O
1 O
× O
10 O
9 O
/l O
and O
platelet O
count O
> O
75 O
× O
10 O
9 O
/l O
. O
The O
use O
of O
prophylactic O
granulocyte O
colony O
- O
stimulating O
factor O
( O
G O
- O
CSF O
) O
was O
not O
permitted O
. O
Lenalidomide O
dose O
was O
reduced O
to O
5 O
mg O
/ O
day O
if O
during O
the O
preceding O
cycle O
neutrophil O
count O
fell O
below O
0.5 O
× O
10 O
9 O
/l O
or O
platelets O
< O
25 O
× O
10 O
9 O
/l O
or O
if O
there O
was O
a O
febrile O
neutropenia O
( O
neutrophils O
< O
1 O
× O
10 O
9 O
/l O
) O
. O

Serological O
response O
was O
assessed O
after O
each O
induction O
cycle O
, O
before O
mobilization O
, O
at O
ASCT B-DESC
, O
3 O
months O
after O
ASCT B-DESC
and O
after O
each O
cycle O
during O
lenalidomide B-DESC
maintenance I-DESC
. O
Bone O
marrow O
( O
BM O
) O
samples O
were O
analyzed O
after O
induction O
( O
RVD O
× O
3 O
) O
and O
if O
a O
near O
complete O
response O
( O
nCR O
, O
normal O
electrophoresis O
but O
positive O
immunofixation O
) O
or O
CR O
was O
reached O
. O
BM O
MRD O
was O
assessed O
first O
by O
multiparameter O
flow O
cytometry O
( O
MFC O
) O
in O
nCR O
/ O
CR O
patients O
. O
Allele O
- O
specific O
real O
- O
time O
quantitative O
polymerase O
chain O
reaction O
( O
ASO O
- O
RQ O
- O
PCR O
) O
follow O
- O
up O
was O
activated O
if O
stringent O
CR O
( O
sCR)/flow O
- O
MRD O
- O
negativity O
was O
reached O
. O
From O
these O
patients O
, O
BM O
sample O
was O
collected O
every O
3 O
months O
during O
the O
first O
year O
and O
every O
4 O
months O
thereafter O
until O
at O
least O
2 O
years O
on O
maintenance O
. O

The O
MFC O
assays O
were O
performed O
in O
the O
laboratories O
of O
five O
Finnish O
university O
hospitals O
. O
BM O
samples O
were O
stained O
with O
monoclonal O
antibodies O
and O
analyzed O
with O
FacsCanto O
or O
FacsCanto O
II O
flow O
cytometers O
( O
BD O
Biosciences O
) O
using O
6-or O
8-color O
protocols O
or O
Navios O
flow O
cytometer O
( O
Beckman O
- O
Coulter O
) O
using O
a O
10-color O
protocol O
. O
Quality O
controls O
were O
performed O
with O
electronic O
files O
and O
comparison O
with O
PCR O
results O
. O
Plasma O
cells O
were O
gated O
using O
CD38 O
and O
CD138 O
antibodies O
and O
light O
scatter O
properties O
. O
The O
expressions O
of O
CD45 O
, O
CD19 O
, O
CD56 O
, O
CD27 O
, O
CD81 O
, O
CD117 O
, O
and O
intracytoplasmic O
Κ O
/ O
λ O
were O
assessed O
in O
all O
samples O
at O
diagnosis O
and O
informative O
markers O
w O
e O
r O
e O
u O
s O
e O
d O
f O
o O
r O
M O
F O
C O
-M O
R O
D O
a O
n O
a O
l O
y O
s O
i O
s O
. O
F O
i O
f O
t O
y O
immunophenotypically O
abnormal O
plasma O
cell O
events O
was O
the O
lower O
limit O
for O
quantitation O
in O
the O
MRD O
analysis O
. O
The O
aim O
was O
to O
collect O
at O
least O
0.5 O
× O
10 O
6 O
total O
nucleated O
cells O
( O
TNC O
) O
to O
achieve O
the O
sensitivity O
of O
0.01 O
% O
. O
The O
median O
sensitivity O
of O
negative O
samples O
was O
< O
0.008 O
% O
( O
< O
0.001 O
to O
< O
0.06 O
% O
) O
. O
The O
median O
number O
of O
TNC O
analyzed O
for O
MRD O
- O
flow O
was O
668,000 O
( O
113,000 O
- O
4,100,000 O
) O
. O

BM O
cytogenetics O
was O
analyzed O
by O
fluorescence O
in O
situ O
hybridization O
( O
FISH O
) O
and O
karyotyping O
in O
the O
laboratories O
of O
genetics O
of O
the O
participating O
university O
hospitals O
. O
BM O
FISH O
analyses O
were O
applied O
to O
CD138 O
+ O
selected O
cells O
for O
IgH O
( O
if O
positive O
, O
screening O
of O
translocations O
4;14 O
, O
14;16 O
, O
14;20 O
, O
11;14 O
) O
, O
17 O
deletion O
/ O
monosomy O
, O
13 O
deletion O
/ O
monosomy O
, O
1q25 O
gain O
, O
1p36 O
loss O
, O
amplification O
of O
chromosome O
9 O
, O
and O
chromosome O
6 O
aberration O
. O

The O
primary O
endpoints O
of O
this O
study O
were O
to O
determine O
( O
1 O
) O
the O
rate O
of O
flow O
- O
MRD O
- O
negativity O
after O
induction O
and O
ASCT B-DESC
including O
the O
CR O
rate O
and O
PCR O
- O
negativity O
rate O
of O
flow O
- O
MRDnegative O
/ O
sCR O
patients O
, O
( O
2 O
) O
improvement O
of O
responses O
during O
lenalidomide B-DESC
maintenance I-DESC
, O
and O
( O
3 O
) O
PFS O
. O
Secondary O
endpoints O
were O
feasibility O
of O
this O
three O
- O
drug O
induction O
combination O
, O
overall O
response O
rate O
( O
ORR O
) O
, O
number O
of O
CD34 O
+ O
cells O
collected O
after O
low O
- O
dose O
CY B-DESC
+ O
G O
- O
CSF O
vs. O
G O
- O
CSF O
alone O
mobilization B-DESC
, O
number O
of O
aphereses O
, O
and O
costs O
according O
to O
the O
mobilization B-DESC
arm I-DESC
, O
graft O
composition O
, O
duration O
of O
treatment O
, O
and O
OS O
. O
The O
results O
of O
the O
mobilization B-DESC
endpoints O
[ O
18 O
] O
, O
graft O
cellular O
composition O
[ O
21 O
] O
, O
and O
cost O
analysis O
of O
the O
mobilization O
substudy O
[ O
22 O
] O
have O
been O
reported O
previously O
. O

The O
primary O
efficacy O
analysis O
was O
the O
intention O
- O
to O
- O
treat O
( O
ITT O
) O
and O
included O
( O
N O
= O
80 O
) O
for O
all O
the O
patients O
who O
underwent O
randomization O
at O
registration O
. O
The O
safety O
assessment O
comprised O
patients O
who O
received O
any O
dose O
of O
the O
trial O
treatment O
( O
N O
= O
78 O
) O
. O
Continuous O
variables O
were O
summarized O
with O
descriptive O
statistics O
and O
categorical O
variables O
were O
summarized O
in O
frequency O
tables O
. O
The O
data O
cutoff O
was O
10 O
April O
2018 O
. O
The O
PFS B-METRIC
was O
calculated O
as O
the O
time O
from O
the O
inclusion O
to O
the O
first O
documentation O
of O
progressive O
disease O
( O
PD O
) O
or O
death O
, O
whichever O
came O
first O
, O
using O
competitive O
risk O
analysis O
. O
The O
OS O
was O
calculated O
as O
the O
time O
from O
the O
inclusion O
to O
death O
or O
data O
cutoff O
. O
The O
event O
- O
free O
survival O
( O
EFS O
) O
was O
calculated O
as O
the O
time O
from O
inclusion O
to O
any O
of O
the O
following O
: O
PD O
, O
death O
or O
withdrawal O
from O
study O
for O
any O
reason O
. O
The O
Kaplan O
- O
Meier O
method O
with O
log O
- O
rank O
test O
was O
used O
to O
estimate O
the O
survival O
distribution O
. O
Competitive O
risk O
analysis O
method O
was O
used O
to O
analyze O
, O
which O
factors O
showed O
independent O
predictive O
value O
for O
myeloma O
outcome O
in O
multivariate O
models O
, O
using O
PFS B-METRIC
as O
outcome O
indicator O
and O
withdrawal O
from O
study O
for O
other O
reasons O
than O
PD O
or O
death O
as O
a O
competitive O
event O
. O
Hazard O
ratios O
with O
95 O
% O
confidence O
intervals O
( O
CI O
) O
and O
p O
values O
were O
reported O
in O
all O
regression O
models O
. O
To O
test O
multicollinearity O
, O
non O
- O
parametric O
Spearman O
correlations O
were O
analyzed O
pairwise O
between O
all O
factors O
, O
with O
2-tailed O
tests O
of O
significance O
. O

Eighty O
NDMM O
patients O
were O
enrolled O
during O
28 O
January O
2013 O
- O
26 O
February O
2015 O
and O
randomized O
to O
the O
mobilization B-DESC
arms I-DESC
. O
Their O
characteristics O
are O
described O
in O
Table O
1 O
. O
The O
median O
age O
was O
63 O
( O
40 O
- O
70 O
) O
years O
. O
Two O
patients O
were O
withdrawn O
early O
( O
neutropenia O
, O
previous O
cancer O
) O
without O
any O
study O
drug O
administration O
. O
Of O
the O
78 O
patients O
who O
started O
induction O
, O
69 O
( O
86 O
% O
by O
ITT O
) O
were O
mobilized O
. O
Fifty O
- O
nine O
patients O
( O
74 O
% O
) O
received O
ASCT O
, O
54 O
( O
68 O
% O
) O
started O
lenalidomide B-DESC
maintenance I-DESC
, O
and O
29 O
( O
36 O
% O
) O
of O
these O
are O
still O
on O
maintenance O
( O
Online O
Resource O
2 O
) O
. O

The O
ORR O
( O
≥ O
PR O
) O
was O
89 O
% O
including O
sCR O
rate O
of O
38 O
% O
, O
CR O
10 O
% O
, O
VGPR O
20 O
% O
, O
and O
PR O
21 O
% O
. O
Flow O
- O
MRD O
- O
negativity O
at O
least O
once O
independent O
of O
serological O
response O
was O
achieved O
in O
53 O
% O
( O
42/80 O
) O
of O
the O
patients O
. O
After O
induction O
, O
29 O
% O
( O
23/80 O
) O
were O
flow O
- O
MRD O
negative O
, O
after O
ASCT B-DESC
35 O
% O
, O
at O
1 O
year O
26 O
% O
, O
at O
2 O
years O
23 O
% O
, O
and O
at O
3 O
years O
after O
ASCT B-DESC
15 O
% O
( O
Table O
2 O
) O
. O
Sustained O
flow O
- O
MRD O
- O
negativity O
for O
≥ O
1 O
year O
was O
reached O
in O
29 O
% O
( O
23/80 O
) O
of O
the O
patients O
. O
PCR O
- O
negativity O
was O
reached O
in O
28 O
% O
( O
22/80 O
) O
of O
the O
patients O
and O
11 O
% O
( O
9/80 O
) O
had O
sustained O
PCR O
- O
negativity O
for O
≥ O
1 O
year O
. O
There O
was O
no O
difference O
in O
serological O
, O
immunophenotypic O
, O
or O
molecular O
response O
rates O
according O
to O
the O
randomization O
arm O
. O
The O
median O
time O
to O
response O
( O
PR O
or O
better O
) O
was O
22 O
( O
14 O
- O
202 O
) O
days O
and O
the O
median O
time O
to O
the O
best O
serological O
response O
achieved O
during O
study O
4.5 O
( O
0 O
- O
45 O
) O
months O
. O
There O
was O
no O
difference O
in O
time O
to O
response O
between O
patients O
with O
HR O
cytogenetics O
and O
those O
without O
them O
. O
The O
HR O
cytogenetic O
group O
( O
20 O
% O
[ O
16/80 O
] O
) O
was O
defined O
here O
by O
the O
presence O
of O
del17p O
( O
any O
percentage O
) O
, O
t(4;14 O
) O
, O
or O
t O
( O
14;16 O
) O
. O
Of O
these O
HR O
patients O
, O
44 O
% O
reached O
sCR O
compared O
with O
36 O
% O
of O
the O
non O
- O
HR O
patients O
( O
p O
= O
0.71 O
) O
. O

Among O
the O
patients O
who O
were O
not O
progressed O
or O
withdrawn O
at O
the O
start O
of O
maintenance B-DESC
( O
N O
= O
54 O
) O
, O
the O
paraprotein O
responses O
improved O
during O
the O
first O
and O
second O
year O
after O
ASCT B-DESC
( O
Table O
2 O
) O
. O
This O
improvement O
was O
statistically O
significant O
between O
the O
start O
of O
maintenance B-DESC
and O
1 O
year O
( O
p O
= O
0.01 O
, O
related O
samples O
Wilcoxon O
signed O
- O
rank O
test O
) O
and O
between O
1 O
and O
2 O
years O
after O
ASCT B-DESC
( O
p O
= O
0.03 O
) O
. O
At O
the O
start O
of O
maintenance B-DESC
therapy O
and O
at O
1 O
and O
2 O
years O
after O
ASCT B-DESC
, O
sCR O
rates O
were O
22 O
% O
( O
12/ O
54 O
) O
, O
24 O
% O
( O
13/54 O
) O
, O
and O
30 O
% O
( O
16/54 O
) O
, O
respectively O
. O
Flow O
- O
MRDnegativity O
, O
regardless O
of O
paraprotein O
response O
, O
was O
achieved O
in O
67 O
% O
( O
36/54 O
) O
of O
these O
patients O
at O
least O
once O
and O
37 O
% O
( O
20/54 O
) O
reached O
also O
PCR O
- O
negativity O
once O
. O
The O
changes O
in O
flow O
- O
or O
PCR O
- O
negativity O
rates O
during O
maintenance B-DESC
therapy I-DESC
were O
not O
statistically O
significant O
. O

Of O
the O
29 O
patients O
who O
are O
still O
on O
lenalidomide B-DESC
maintenance I-DESC
at O
the O
cutoff O
point O
, O
17/29 O
( O
59 O
% O
) O
are O
in O
sCR O
, O
4 O
( O
14 O
% O
) O
in O
CR O
, O
7 O
( O
24 O
% O
) O
in O
VGPR O
, O
and O
1 O
( O
3 O
% O
) O
in O
PR O
. O
The O
paraprotein O
response O
of O
these O
long O
- O
term O
responders O
deepened O
significantly O
during O
the O
first O
( O
p O
= O
0.004 O
) O
and O
the O
second O
( O
p O
= O
0.011 O
) O
year O
after O
ASCT B-DESC
on O
maintenance B-DESC
but O
not O
during O
the O
third O
year O
( O
p O
= O
0.180 O
) O
. O

With O
a O
median O
follow O
- O
up O
of O
27 O
( O
0 O
- O
59 O
) O
months O
, O
neither O
median O
PFS B-METRIC
nor O
OS O
have O
been O
reached O
. O
The O
PFS B-METRIC
at O
1 B-RESULTS
, I-RESULTS
2 I-RESULTS
, I-RESULTS
and I-RESULTS
3 I-RESULTS
years I-RESULTS
after I-RESULTS
inclusion I-RESULTS
was I-RESULTS
78 I-RESULTS
% I-RESULTS
, I-RESULTS
67 I-RESULTS
% I-RESULTS
, I-RESULTS
and I-RESULTS
52 I-RESULTS
% I-RESULTS
, O
and O
OS O
96 O
% O
, O
90 O
% O
, O
and O
83 O
% O
, O
respectively O
. O
Median O
EFS O
was O
24 O
months O
( O
95 O
% O
CI O
9 O
- O
39 O
months O
) O
( O
Fig O
. O
1 O
) O
. O
The O
median B-METRIC
PFS I-METRIC
for O
the O
Revised O
Multiple O
Myeloma O
International O
Staging O
System O
( O
R O
- O
ISS O
) O
stage O
3 O
group O
was O
only O
eight B-RESULTS
( I-RESULTS
95 I-RESULTS
% I-RESULTS
CI I-RESULTS
0 I-RESULTS
- I-RESULTS
27 I-RESULTS
) I-RESULTS
months I-RESULTS
and O
was O
not O
reached O
for O
the O
other O
groups O
. O
For O
the O
patients O
who O
started O
maintenance B-DESC
( O
N O
= O
54 O
) O
, O
PFS B-METRIC
at O
1 B-RESULTS
, I-RESULTS
2 I-RESULTS
, I-RESULTS
and I-RESULTS
3 I-RESULTS
years I-RESULTS
after I-RESULTS
inclusion I-RESULTS
was I-RESULTS
94 I-RESULTS
% I-RESULTS
, I-RESULTS
80 I-RESULTS
% I-RESULTS
, I-RESULTS
and I-RESULTS
65 I-RESULTS
% I-RESULTS
and O
OS O
100 O
% O
, O
96 O
% O
, O
and O
87 O
% O
, O
respectively O
. O

If O
flow O
- O
MRD O
- O
negativity O
was O
achieved O
and O
sustained O
for O
at O
least O
1 O
year O
, O
the O
median B-METRIC
PFS I-METRIC
was O
not O
reached O
compared O
with O
the O
patients O
who O
achieved O
flow O
- O
MRD O
- O
negativity O
but O
lost O
it O
below O
1 O
year O
( O
median B-METRIC
PFS I-METRIC
33 B-RESULTS
months I-RESULTS
; I-RESULTS
95 I-RESULTS
% I-RESULTS
CI I-RESULTS
27 I-RESULTS
- I-RESULTS
39 I-RESULTS
) O
and O
to O
the O
MRD O
- O
flow O
- O
positive O
patients O
( O
median B-METRIC
PFS I-METRIC
15 B-RESULTS
months I-RESULTS
; I-RESULTS
95 I-RESULTS
% I-RESULTS
CI I-RESULTS
9.9 I-RESULTS
- I-RESULTS
20.1 I-RESULTS
) I-RESULTS
, I-RESULTS
p I-RESULTS
< I-RESULTS
0.001 I-RESULTS
( O
Fig O
. O
2a O
) O
. O
The O
median O
OS O
was O
not O
reached O
for O
any O
of O
these O
groups O
( O
N O
= O
69 O
, O
p O
= O
0.01 O
) O
. O

Of O
the O
patients O
who O
achieved O
PCR O
- O
negativity O
for O
at O
least O
1 O
year O
, O
11 O
% O
( O
9/80 O
) O
, O
none O
have O
relapsed O
to O
date O
. O
The O
median B-METRIC
PFS I-METRIC
( O
p B-RESULTS
= I-RESULTS
0.044 I-RESULTS
) O
( O
Fig O
. O
2b O
) O
or O
OS O
( O
p O
= O
0.443 O
) O
was O
not O
reached O
either O
in O
this O
group O
or O
groups O
with O
PCR O
- O
negativity O
less O
than O
1 O
year O
or O
PCR O
- O
positive O
. O
No O
statistically O
significant O
differences O
were O
seen O
in O
terms O
of O
IMWG O
, O
R O
- O
ISS O
, O
ISS O
, O
age O
, O
gender O
, O
or O
study O
arm O
between O
sustained O
flow O
- O
MRD O
- O
negativity O
group O
and O
others O
or O
between O
sustained O
PCR O
- O
negativity O
group O
and O
others O
, O
but O
the O
number O
of O
PCR O
- O
negative O
patients O
was O
small O
. O
Nine O
patients O
have O
reached O
sustained O
PCR O
- O
negativity O
and O
only O
one O
of O
them O
had O
HR O
cytogenetics O
. O

The O
median O
follow O
- O
up O
of O
all O
patients O
( O
N O
= O
80 O
) O
is O
27 O
( O
0 O
- O
59 O
) O
months O
and O
for O
those O
patients O
( O
N O
= O
54 O
) O
who O
started O
maintenance O
43 O
( O
8 O
- O
59 O
) O
months O
. O
The O
median O
duration O
of O
lenalidomide B-DESC
maintenance I-DESC
therapy O
is O
so O
far O
33 O
( O
0 O
- O
51 O
) O
months O
. O

To O
date O
, O
29 O
of O
the O
total O
of O
80 O
patients O
( O
36 O
% O
by O
ITT O
) O
are O
still O
on O
maintenance B-DESC
treatment I-DESC
. O
Of O
those O
54/80 O
patients O
who O
started O
maintenance B-DESC
, O
25 O
( O
46 O
% O
) O
have O
discontinued O
it O
, O
19/54 O
( O
35 O
% O
) O
due O
to O
PD O
, O
four O
due O
to O
side O
effects O
, O
and O
two O
by O
their O
own O
will O
. O
Five O
( O
6 O
% O
by O
ITT O
) O
patients O
who O
received O
ASCT B-DESC
did O
not O
start O
maintenance B-DESC
at O
all O
: O
two O
due O
to O
PD O
, O
one O
due O
to O
severe O
rash O
during O
induction O
, O
one O
by O
investigator O
's O
decision O
, O
and O
one O
proceeded O
to O
allogeneic O
stem O
cell O
transplantation O
. O

The O
median B-METRIC
PFS I-METRIC
and O
OS O
for O
the O
HR O
patients O
were O
only O
15 B-RESULTS
( I-RESULTS
95 I-RESULTS
% I-RESULTS
CI I-RESULTS
5 I-RESULTS
- I-RESULTS
25 I-RESULTS
) I-RESULTS
and O
54 O
( O
12 O
- O
54 O
) O
months B-RESULTS
, O
respectively O
. O
In O
the O
no O
- O
HR O
group O
, O
PFS B-METRIC
( O
Fig O
. O
3a O
) O
or O
OS O
( O
Fig O
. O
3b O
) O
were O
not O
reached O
. O
The O
estimated O
median O
EFS O
for O
HR O
and O
no O
- O
HR O
patients O
was O
eight O
( O
95 O
% O
CI O
0.4 O
- O
16 O
) O
months O
vs. O
not O
reached O
, O
p O
< O
0.001 O
. O
Only O
one O
HR O
patient O
achieved O
sustained O
flow O
- O
MRD O
- O
negativity O
, O
six O
were O
in O
non O
- O
sustained O
group O
, O
and O
six O
in O
the O
MFCpositive O
group O
( O
p O
= O
0.079 O
) O
. O
In O
the O
HR O
group O
, O
11 O
patients O
( O
69 O
% O
) O
have O
relapsed O
to O
date O
compared O
with O
25 O
( O
39 O
% O
) O
in O
the O
non O
- O
HR O
group O
( O
p O
= O
0.033 O
) O
. O
Four O
HR O
patients O
have O
withdrawn O
from O
the O
study O
. O
Eight O
HR O
patients O
started O
lenalidomide B-DESC
maintenance I-DESC
but O
seven O
of O
them O
have O
relapsed O
after O
a O
median O
of O
only O
6 O
months O
on O
maintenance O
. O

To O
test O
the O
predictive O
impact O
of O
different O
variables O
on O
PFS B-METRIC
, O
gender O
, O
age O
≤ O
or O
> O
65 O
years O
, O
study O
arm O
, O
World O
Health O
Organization O
( O
WHO O
) O
performance O
status O
, O
IMWG O
group O
, O
R O
- O
ISS O
, O
ISS O
, O
HR O
cytogenetics O
, O
best O
serological O
response O
( O
sCR O
vs. O
CR O
/ O
VGPR O
vs. O
PR O
/ O
worse O
) O
, O
and O
achievement O
of O
flow O
- O
MRD O
- O
negativity O
or O
PCR O
- O
negativity O
were O
tested O
with O
multivariate O
analyses O
. O
In O
correlation O
analysis O
, O
there O
proved O
to O
be O
high O
pairwise O
correlations O
, O
between O
0.677 O
and O
0.773 O
between O
flow O
- O
MRD O
- O
negativity O
, O
PCRnegativity O
, O
and O
serological O
responses O
, O
and O
due O
to O
this O
multicollinearity O
, O
these O
three O
factors O
competed O
for O
the O
same O
predictive O
power O
. O
In O
multivariate O
analysis O
, O
only O
one O
of O
them O
, O
achievement O
of O
flow O
- O
MRD O
- O
negativity O
, O
provided O

Adverse O
events O
( O
AEs O
) O
were O
assessed O
from O
all O
the O
patients O
( O
N O
= O
78 O
) O
who O
received O
at O
least O
one O
dose O
of O
trial O
treatment O
. O
Lenalidomide B-DESC
maintenance I-DESC
AEs O
were O
separately O
assessed O
from O
the O
patients O
( O
N O
= O
54 O
) O
who O
received O
at O
least O
one O
dose O
on O
maintenance B-DESC
therapy O
. O

AEs O
grade O
3 O
or O
higher O
are O
reported O
in O
Table O
3 O
. O
Hematological O
and O
infectious O
AEs O
were O
the O
most O
common O
. O
During O
RVD O
induction O
, O
17 O
( O
22 O
% O
) O
febrile O
neutropenic O
events O
were O
reported O
. O
The O
rate O
of O
severe O
peripheral O
neuropathy O
was O
low O
, O
only O
3 O
% O
. O
Treatment O
- O
related O
mortality O
for O
the O
whole O
protocol O
was O
1 O
% O
. O
During O
induction O
, O
one O
patient O
died O
due O
to O
hepatorenal O
syndrome O
caused O
most O
probably O
by O
bortezomib B-DESC
( O
autopsy O
) O
. O

During O
the O
lenalidomide B-DESC
maintenance I-DESC
, O
28 O
( O
52 O
% O
) O
patients O
had O
grade O
3 O
neutropenia O
, O
6 O
( O
11 O
% O
) O
grade O
4 O
neutropenia O
, O
and O
11 O
( O
20 O
% O
) O
had O
febrile O
neutropenia O
. O
Lenalidomide B-DESC
dose O
was O
reduced B-DOSAGE
from I-DOSAGE
10 I-DOSAGE
to I-DOSAGE
5 I-DOSAGE
mg I-DOSAGE
per I-DOSAGE
day I-DOSAGE
in O
16/54 O
( O
30 O
% O
) O
patients O
. O
Reasons O
for O
dose O
reductions O
were O
neutropenia O
in O
ten O
( O
63 O
% O
) O
, O
neutropenic O
pneumonia O
in O
one O
, O
rash O
/ O
urticaria O
in O
three O
, O
grade O
3 O
thrombocytopenia O
in O
one O
, O
and O
vertigo O
and O
cephalalgia O
in O
one O
patient O
. O

Maintenance B-DESC
treatment I-DESC
was O
permanently O
discontinued O
due O
to O
side O
effects O
in O
four O
patients O
: O
two O
for O
rash O
, O
one O
for O
interstitial O
pneumonia O
, O
and O
one O
for O
SPM O
( O
basalioma O
) O
. O
These O
patients O
are O
in O
the O
follow O
- O
up O
and O
three O
of O
them O
have O
not O
progressed O
within O
the O
follow O
- O
up O
. O

Two O
SPMs O
( O
2.5 O
% O
) O
have O
been O
reported O
so O
far O
. O
One O
patient O
had O
facial O
basalioma O
during O
maintenance B-DESC
and O
one O
patient O
had O
previously O
discontinued O
maintenance B-DESC
due O
to O
the O
rash O
after O
2 O
months O
of O
use O
, O
and O
1 O
year O
later O
, O
grade O
3 O
squamocellular O
carcinoma O
of O
the O
left O
tonsilla O
was O
diagnosed O
. O
This O
patient O
is O
in O
remission O
after O
chemoradiotherapy O
. O